Sweden · Delayed Price · Currency is SEK Active Biotech AB Company Description
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden.
It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors.
The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy.
Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
| Country | Sweden |
| Founded | 1983 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Helen Tuvesson |
Contact Details
Address: Scheelevägen 22 Lund Sweden | |
| Phone | 46 46 19 20 00 |
Stock Details
| Ticker Symbol | ACTI |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0001137985 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Helen Tuvesson Ph.D. | President and Chief Executive Officer |
| Hans Kolam | Chief Financial Officer |
| Dr. Erik Vahtola M.D., Ph.D. | Chief Medical Officer |